- Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings and welcome to the TG Therapeutics Third Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jenna Bosco. Thank you, Jenna.

You may begin.

Jenna Bosco

you. Thank thanks this and joining for everyone, morning. us Welcome, and me discuss and our the Jenna our a Bosco, Chief quarter Chief to Officer. with and Chairman Weiss, Sean Michael results I’m Commercialization third Officer; Adam Power, today XXXX update are Executive and Chief Officer; business our Waldman, provide Financial financial

provide an to overview a the and corporate developments, recent Following Harbor our our efforts, our of statement, Safe overview to call commercialization will brief Mike the update provide financial of Sean turning our will session. Q&A will the provide an before begin on Adam results operator over

these Act remind forward-looking include statements XXXX. about we clinical I’d meaning performance, These our Private the expectations may for SEC factors are from statements be Before and Therapeutics operating marketed milestones, anticipated regulatory products. can sales risks we and indicated. development subject differ Reform will pipeline the including everyone and include various cautions operations our our plans statements TG that like financial of found may that our Factors within filings. projected be performance, making to actual forward-looking to those in forward-looking to materially results of begin, statements affect that future Litigation that Securities cause risk that TG

representing only www.tgtherapeutics.com, will available XX In specifically statements. addition, audio on being for as next any obligation disclaim rebroadcast it as days. subsequent today, views This any or of be at as call website to any views is the should call made and forward-looking update revise for TG’s be recorded on our forward-looking where date. upon our statements of represent not relied this We any

turn Mike to call like our Weiss, I’d to CEO. over Now, the

Michael Weiss

us call. on Jenna good joining thanks morning, everyone the and for Thanks, and

The team a our commercialization came for of the plans. pre-launch XXXX very execute really as quarter to was time TG productive together on third

if evaluated to toward work streamlining are goal and and in approved, launch for was other goals year. our an my am will vantage approved, our previously, few quarter more we and launch our We and quarters. ublituximab. multiple active to reducing the million, multiple am submission report our ublituximab substantially of been for across us our Steinman mentioned the ensuring patients prepared infusion relapsing to option Stanford a resources prior have compared this minimize burn remind enrolling to Dr. relapsing our join we months every ublituximab X-hour dose. remain treatment was extremely focusing that next following that is forms just forms be FDA me of all committed early ublituximab. potential additional to for launch in As offering our potential Phase first and from that, referred to sclerosis progress all meaningful reserving and believe year approximately supporting X to highly details and of potential moving University. Also a have savings was approval planning administered minutes, Lawrence ublituximab the in Phase while necessary the some if to BLA third pleased the a quite efforts also The that with expenses. to of around and nicely. guided but X these along patients teriflunomide, us point to were play and provide our that X,XXX cost Waldman, sclerosis, the I dedicate of of by were provide ultimate Officer, our has X as approximately to or goals countries successful shortly approval role achieve eliminate $XX trials convenience let of resources Chief burn overall MS, hard proud the in that launch ublituximab Power, treatment I support required X from for program Commercialization financially while Adam of details, which realize XX the we our positioned a down join our work team seems to well effort these CFO, RMS. led We’ve I’ll Sean of be everyone to the X in With for will

ublituximab to met rate, studies teriflunomide. their relapse demonstrating an noted the as significant ARR, in referred As with compared statistically a treatment primary past, annualized both endpoint also reduction to

ECTRIMS. results, sub exploratory Multiple as analysis endpoint the believe data profile, of to team RMS, support with positive the recently, for potential if Sclerosis the I RMS. am for set, Annual at the further KOLs X and to was Congress present we encouraging primary this European ublituximab refer the which in the meeting encouraging, going data over highly around sets believe past the opportunity In to numerous XXXX an during patients we presented Research received present this continues Treatment data year ublituximab treatment to show to the for addition ublituximab engaged to to with approved. with The Committee of treat and and feedback the Most patients additional we’ve had of profile the had opportunity different we the for several the we

‘XX. meeting second approval will discussions additional treatment along approved. the moving in commenced. of make action December approved, the hopeful and ublituximab with the And mention late that of from excited months XXXX. confirm if provide regulatory to on of process, in EU update an are I that in XX, not many be of timing past, approval for less half on where than date the interactions we have with We color need in We to will that to FDA can front, the have efforts potential that patients the with EMA On occur target provide we’ll options. perspective, will remain recently also would could a ublituximab our we be available we are are X the but with RMS as labeling the cycle like any the PDUFA we completed

the assessing go-to-market still or and U.S. go ex Europe, it evaluate to we continue partner whether to whether are in to alone We strategy

that, Chief Officer, let the RMS. his as over on in potential turn with preparation our to some and the quarter opportunity me Waldman, Commercialization for as on thoughts our plans share quarter well So Adam call to Adam? the ublituximab past of thoughts commercial

Adam Waldman

truly am in you, MS made chronic activities, anticipated the our considerable a sclerosis. Thank debilitating months, provide X of is on believe significant the natural multiple course several I excited update to new preparation X approximately starting of an transformed families. way have the we life forms over Today, treated go and and CDXX physicians patients for of class the The their that commercial the on can using disease. morning, quality on has have good MS significantly as that CDXX. last the disease these and to agents our of Mike, is everyone. relapsing impact ublituximab of on a a early launch progress impact patients will may every therapy

We our were highest started potential To market to we in success capture And we across with team this to second in have shows end, teams of of there seen understood strong be MS the these space how launched. would a hire we we have MS that fact, the field share. the professionals people our one knowledge market. from deep agents fit profile. moment been meaningful and quarter working believe This the that relationships based in keys of market hand-selected our growing was In that to XXXX, target data and community. the of usage commercial is experienced methodical large share hired has on of the have a have research, the CDXX and that a we since landscape market ublituximab

adding Over up have the sales field-based roles and months, ramped support. sales, reimbursement in hiring and we leadership significantly access customer-facing critical last several our

will Our point, these payers have for XX the as hiring for payer to XX At hired teams goals of weeks regional experience. launch. months. industry to years our as several we marketing members, which on field-based medical our last MS average well joined teams, hires been team previously next engaging team have the and this plus our internal working providers prepared and the our and hiring training and They finalize be have for be we met field-based over of

important how knows to ensure to once also this access drug patient community we is ublituximab, team to provide the to approved. working is it everything can to Our get we hard and do

the practices in and physicians is for navigating of reimbursement from general frustrations therapies. access biggest and process the of One

capabilities in as team of last emphasis a as the area. We significant the made ensuring I be ublituximab on have, our access building possible. process will several months our to therefore, has seamless extremely proud am that progress this placed

with from great national clinical teams a been issues we ublituximab are our over do payer profile positive, perspective, reimbursement. the major has doing engaging on with regional any for account payers last and the a First, of foresee national not year. Feedback job

the However, with XXX days through will XX need over new first any to launch. processes product, their to work post payers

formularies understanding institutional include of on process the place excellence as centers key formulary plans Second, we to MS the their have made as considerable have in ublituximab to progress with and soon possible. work

patients we component MS opt access. is support of the into another this And programs. ensuring that critical Third, of will majority know patient

are build a believe what best-in-class support worked launch very we customers And have we be program We patient be approved. on track ublituximab, once to key to alongside program. closely to ready this with we will what

for summary, experienced accelerated reimbursement we strengthening of team launch. capabilities to has the facilitate months, organization our the In possibility ublituximab. work now tremendous few building with last which the we we over access on the access and as field-based an hired progress last ublituximab to have made Lastly, XX months accounts and ready will have over that commercial

an their experienced, team, more conferences, MS groups pound-for-pound other a any advocacy we believe ramping engaging key neurologists, have actively boards than engagements. MS participants if community in KOLs, and the incredible industry. so, are teams team payers activities, advisory at built basis These not which is in community, and up as on We the

grow attention, very our the ublituximab’s resources launch of a positive at across continues and have represents the focus confidence commercial this has our opportunity Our profile are making commercial to we built believe team success. feedback as this been commercial board. and on aimed a the and We way all significant

as with be going of we move I’m over sense to for approved, debilitating to disease. ublituximab, important to We a purpose and will Sean. continue an hand with know this patients urgency it managing new if that, option forward And

Sean Power

thanks, corporate which Earlier, be our Financial and XXXX Investors Media morning. can Adam, for Results, this quarter section you, of our joining viewed detailed Thank website. & Third us everyone, we the on reported

securities. a third million additional That, coupled position. We approximately XXXX. cash sufficient on our beginning focus I’ll the will Hercules in highlights call, upon investment today’s to $XXX equivalents few cash, be our ended cash us facility under with with the the ublituximab quarter, available with into For believe approval, and capacity from quarter we

that burn well said, prior below $XX under will quarters, We along guided determined $XX and approximately focused with are for to which quarter preparations quarter, and million the ublituximab, of of at as landing XXXX for measured also quarters. report savings which we cost the future result range third launch pleased the to million some our our Mike of of is $XX our previously incur the in upcoming our for differences, million, timing

$X.XX a QX third approximately million of quarter decrease of per or where net saw $X.XX $XX approximately share. share, from net a million XXXX million Our which the of we $XX $XX was or ‘XX, for almost GAAP loss was of loss per

our or months was a or for ended net loss more to representing launch share decrease driven a the quarter decrease shift our SG&A, compared was September million of of operations $X.XX year and than R&D primarily $XXX.X $XXX.X share by net X in to development quarter, and across-the-board in loss decreases XXXX, and XX, net preparation compared of XXXX, oncology $X.XX MS the a in per streamlining comparable efforts. to GAAP The a $XXX million As million in the loss per focus the prior to due for period-over-period.

to our end quarter call $XX and project the the of million, conference year. Q&A. positioned of In $XX begin expect million the that, through over anticipated XXXX the leaves us moving well I we we at now we to back between With operator to the turn terms believe for burn be the of fourth which will the MS forward, what PDUFA

Operator

with Thank your question is with C. you. Ed proceed Wainwright. White from first [Operator Our Please Instructions] H. question.

Ed White

Good morning. my questions. for taking Thanks

your is mentioned that And like be prior on expectations to What should Would just for then that the when come approval? describe the So opportunity had second you ‘XX, think? Or you’re something as far as how like? are can do market going the that? to you Europe? half something What you EMA partnering, would is to Or timing – in expect be partner, do after if of it? hear describe the the – that we approval? would you

Michael Weiss

thanks Hey, for the Ed, question.

EU opportunity interesting. the So is

overall obviously I think but so reasonable – a XX%ish large of the of market so the EU currently opportunity size that’s for the it’s not [indiscernible] about piece market, it’s CDXXs, portion. a

So of that in us. it’s for is Germany. in Most of focus not high a terms dollars

The other countries, in lot they less. a are but it’s there, obviously,

So the organization own. as and it we our from in out think opportunity think then probably we I setting we on think be spread get an would about Germany there, about we and Europe, up potentially focused if

again, could it very advance. to launch, is say of happen after In running our partnership, launch ultimate speculative. partner of timing, it’s But then would always before we but have not in would terms a timing if invariably been decision I to there, we’re any

Ed White

thinking Okay, cutting. about guidance that? What that we about are expense should done on we just thanks, SG&A we And the R&D being gave how Mike. how thinking the should in on an You line? incredible for should How up the And going I’m job forward? some be be you’ve opportunities? R&D cost quarter. expenses thinking consider of

Michael Weiss

down. that to trials expect to completely Again, expenses continue go just would down. still I oncology the have Yes, that shut will R&D are hard we

around be in carrying MS So will still. additional not studies they potentially as continue will expenses we those go – some to down, that. outside ublituximab starting and of we we’re probably, of probably But

up the think it other down to for the wants half second I or about, back go any in maybe then So Sean and next in, quarter to it probably two, next continues to right Sean, or but of is chime color? starts year. that creep

Sean Power

fair, Mike. think Yes. No, that’s I

Ed White

Great. Thanks for my question. taking

Michael Weiss

Thanks, Ed.

Operator

you. Thank

from proceed question next question. Howerton your is with Please Jefferies. Chris Our with

Chris Howerton

dynamics I Great. doing better kind of Thank the you a launch. been so commercial much. questions to on bit ask a little expected the wanted just couple of has ofatumumab in

differences in targeting how was there two. between the dosage CDXXs, curious I some So you or patient be differential about would physician if between thinking were and those maybe forms

might I so expiry that the question housekeeping I Thank have you And be as that question. you’re our would of then just is at of one thing second So was model. What the is kind looking IP a kind expecting continue. latest much.

Michael Weiss

Sure.

think are the entitled XX, I patents market extension with XX approval, side, the a IP the is ublituximab, assuming on an term exclusivity will So for patents years there for basic we be biologics. to XX

us late ‘XX into sorry. would the for years, XX put that sorry, late very So, ‘XX or ‘XX ‘XX ‘XX early actually very, or

Sorry about that.

time have and for on spent patents then talking – So about XX do some haven’t go years other could we much X, another we plus. that

But will some let interesting of it’s the markets. the forms. got a relativity somewhat So good scenes. patents dosage it. the we your runway we’ve behind biologic become really with terms discuss with and two I potential think and with pretty the I’ll question, It’s Adam briefly patents other first answer in

the and these to doctors patients I might engagements yesterday month. not the role for But prescribers who differently get once most in view most actually settings in in that patients it MS provider. physicians travel has them. want they are think distances that their to in even subcu a which seem heard somewhat patients with and we products Most does just their dealing different one-on-one use nice a interested disease to the

market it there to that’s the they is out as an had on. capping market. does their people share we come there. overall grow you they on whether feel as Obviously, subcu effect because, represents continues of stay about on, probably know, so accumulation early that XX% like And projected And are

share. but – close of dynamic their between market. and and dynamic XX% And the of getting share So is that’s XX% cap, think it’s kind we see where to I the

patients XX% will the So about I an color. going more it’s go of XX%, subcu. and think receive to how CDXX we the will that’s out. about About shake to add please we some Adam, continue continue IV with to believe

Adam Waldman

that I The like add rural to in market perhaps does Mike more general exactly launch, perhaps seem would areas what Mike. thing much said seem continued But with I much pretty excellence I KESIMPTA it is the would pretty it, the expand, like does market outside the centers more think you only neurologists. covered of it and has is say. what

Chris Howerton

guess, – then that Okay. follow-up, guess, have think? you And Adam, of it, be IV maybe and you as you’ll course, about do visibility, Mike entertain more that versus targeting would those a just physicians of likely I subcu, minor are kind how you would do to thinking if prescribe I you to,

Adam Waldman

I’ll can start, add. Mike, Yes, and we

centers MS capabilities. excellence that of think I infusion have

capabilities to practices and in a where terms will community think infusion start we think be. of to place have IV would sense I that usage make be logical continue predominantly

the centers And believe so should focus and and infusion those I large majority of is is excellence the we initial – that for seen OCREVUS is with in where us very these use MS of centers large think capabilities. community be

Michael Weiss

I Ventec add interesting huge neurologist concentrated the place KESIMPTA something we teams Chris, environments, excellence in from think more they who large business, are that going may going I we’re has be far think referred of I’ll for capabilities the after have I I been The neurologists, community just again, as of pushing CDXXs, do an that Adam to again, best those vast Roche, that, something obviously, to be think mentioned, are think, large the to. a be Adam it’s the the is effort when rural both general to been for And the think, centers But those out and don’t and that’s, physician. or still of as about like business for into Novartis areas vest their they for highest where OCREVUS there. the nice might like practices. to get into getting and us, Yes. general XX% ROI is close majority in KESIMPTA. current us, sites infusion

Chris Howerton

more excellent. efficient a too. And That business Okay. sounds sounds it model, like,

So, thanks, guys.

Michael Weiss

Yes, thanks, Chris.

Operator

Thank you.

Our from with proceed Ladenburg Matt next question. Please Kaplan is with your Thalmann. question

Matt Kaplan

progress, congrats my and for guys. the taking thanks on Hi, questions,

Michael Weiss

Thanks, Matt.

Matt Kaplan

you impact Just on, well? little you forward, think you question and programs than Chris’ can their what those a program take how will comment wanted subcutaneous dose as bit high other I Roche’s do guess, more said? to the market And

Michael Weiss

Yes.

chime high we programs. And know we about don’t years, potent to that then to I’ll mean, ton Adam, subcu go could certain give take. any I say strategy where the activity on available to their you than or better with more from in. first, the think think potentially, be don’t really a know the we visibility next So is could our CDXX. X try with have off in into high-dose perceived other the comp those I I dose, good are they that timing, potentially of

we for the get see them. think I it’s a again, out So take the works going to time material patient. But to into them will long that how

out. we’re a product. other I don’t them. successful. formulation. So know subcu The have subcu, products, mean competitive is been advantages again, an number are The some others so and I very used where provide which every it side, not of strategy months additional the with the is to convenient about been a issues there delivering of jury that, concerned of been have think infusion for I successful, think I extremely I that’s don’t going think that a X-hour way think in still it’s of overly a X that’s subcu lot

any how the on is Adam, see them. goes anything think So that further, color? we I for it out jury will

Adam Waldman

I Yes, covered you Mike. it, think

think this wait the from a we perspective. profile overall that the the to market, aspect believe perspective, also and from an is that it’s we a looks a important think do adds patient and actual of what’s an matter I convenience, but what’s monitoring and does see like I of streamlining in experience, convenience from both but that experience office required time post interesting all from will what pre-medication –

So, continue want best to a therapy. a for we twice also year important. believe convenience B-cell believe be But we hour we is will patients who positioned quick that one

Matt Kaplan

approval, And in you plans Okay. ublituximab. – Thank Can continued following future? the – you that mentioned your development for you. of can you you MS about for PMS, talk plans progressive

Michael Weiss

Yes.

are don’t we to any in and are plans we a but think with they design area. have be successful certainly that trial to been we So, I think discuss KOLs that what understand area. exploring engaging needs have would what today, the

Matt Kaplan

following it and question, what look last like size, then will your in Adam. is from I maybe And footprint I for guess of approval, commercial the guess now? where team Okay. the terms

Adam Waldman

Yes. Thanks Matt.

good are point. much position pretty in We this at

internal a is we in we good XX that from to the excellence, timelines position business. in And As know feel be remarks in that early think where I our we were past that to ready of and a said hiring. that, like be are be will is, hit to centers approach. think have launch what as order for mentioned have right think team MS now, we come for community about to than our to of and prepared adequate We is is field-based have we will in have talking I the going we I focus. our somewhat cover there, our large We we perspective footprint We targeted this next a about get think a with Chris people. and year. more centers we XXX go

Matt Kaplan

good lot a and Thanks December. Great. going to

Michael Weiss

Thanks Matt.

Operator

you. Thank

is question question. JPMorgan. Eric from Joseph with with Please next proceed Our your

Eric Joseph

curious And just by And know when co-pays to taking Good it your alternatives monetization? to cash expand much are any you am question. patient? the can opportunity you perhaps the being little to XXXX, risk open then to there get and just access just support to the financing just price. then to strategy position. Thanks a latest with wondering compete on capped is perspective? bit Thanks. royalty I finally, launch, I Can the for your be whether from noted borne are how also patient comes if considering I curious sense morning. through would of am Sean symptom on payers sensitive

Michael Weiss

Thanks. you to question? take the do Adam, want first

Adam Waldman

Yes. Thanks Eric.

think perspective. very are from well going we I access to a compete patient

we best-in-class patient built mentioned, I program. have a As support

have support will of We all that initiatives the have. companies these

we co-pay specifically we to have co-pay feel patients. program, sensitivity good support a program, payers a price. and second a and that was about are You question will we practices to then in asked And around and your position

idea I we and I how have They are gotten heard cost, net at have in want think developed looking into just where from I think have that are And interested are sensitive understand an is I We launch. going we to payers think this they what price low they we the inviting say, our for feedback are competition market. – to, and into the cost. net them. of would lowest

Michael Weiss

and we of money we on And are But any in open think we to in going day keeping Great. terms not want money want add. terms we the continue of cash plenty ideas – into ‘XX. all to We one, obviously, to rush. move of alternative are launch have how Eric, position get to in doors financings, on to be I

up we are while money situation. the most So, be Obviously, we anyway, running. are not everything getting will not of an sitting but overfunded, emergency in that and bank

potential yes, burn of get to we extend And the we plenty also options. revenues lot number. which the So, the are to year, expecting phase. depending others, position, may on we even market other to the by table, monetizations I the a though cash will are good have royalty first whole financings our And course, not when drive feeling launch as about some like in we are conditions of XXXX think quite look it on

Eric Joseph

Okay. Thanks December. taking going good luck the through for questions and

Michael Weiss

Thanks Eric.

Operator

our proceed And next Mamtani you. your question. Mayank Thank Riley. with question with Please from is B.

Sahil Kazmi

warning for differentiated Sahil Hi. how we And date? questions getting What PDUFA labeling be expectations are of potential asking the closer could interactions the as from is Kazmi a team. accretives, morning the for are Good Mayank. This for to section your example? couple

Michael Weiss

Yes.

the So, thanks question. for

we have in So, – the further of did commenced, to discussions disclose are earlier going terms we but that any provide not color. labeling

more know it So, second question. your have thing to to anything same goes I if the and I as don’t part add of

Sahil Kazmi

for And the on ISO maybe of Great. your kind came you navigating are any payer recent report just just how Okay. Adam then line discussions that as well. out, of more top of thoughts through the on some broadly

Michael Weiss

I will Adam and take lead the let it. off obviously we to over. report, are have reviewing, I But ISO continue Yes. will review

We probably ISO’s try some we it, how point comments generally speaking, will to comments was drug. some There official the have to price on a is the why pricing. we report getting mean reason was my in how at soon. all think clear put we try they affect opinion, about influence role with before report out launched. I But the to about, whole us to

thinking been you at a about point. price we always lower in have know, As coming

I but maybe skewed point, environment. is just of concept, are their access I will but think the care to the make us for analysis address not overall and it’s some a Adam So, certainly let

Adam Waldman

Yes.

about view value our reacted we payer strategy is I to report in haven’t remarks bringing to to affect our good And as we going I reimbursement ublituximab feel we ISO from coverage. it’s the and don’t and and really a mentioned feel we with about we and and proposition the about with our think specifically, don’t pricing what regards issues think are foresee with major payers access I the good feel thinking that perspective it. confident, are mean

Sahil Kazmi

best questions PDUFA. for of taking Thanks Excellent. and our luck for

Michael Weiss

you. Thank

Operator

Thank you.

with with proceed Prakhar Cantor. from question. Agrawal is your question next Please Our

Prakhar Agrawal

thanks all questions, and morning taking Good and my on the Hi. congrats for progress.

So, firstly, a quick clarification.

and drug And for also If of the your if FDA? you you inspections supply any in readiness can follow-up. terms talk us are could a had remind I there left if at about launch,

Michael Weiss

Yes.

haven’t we on any again, provided inspection. So, color

So, part. what to that pass on I was second question. am the And going

Prakhar Agrawal

Readiness drug supply in launch? terms of at

Michael Weiss

for drug of Yes, we supply have launch. plenty

we large Samsung a comfortable manufacturing have are Biologics, We arrangement supply. with and launch our with

Prakhar Agrawal

Okay. mentioned Mike, data few you past at over And you the months. secondly, the presented several times

their willingness hearing excited ubli them So, of to from what really you. the factors. what’s switch you some from specialists Ocrevus? about on gets Thank loyalty key about also, talk what are And

Michael Weiss

question. the for Thanks Sure.

So, when we and the to itself. physicians, is data And of is data we aspects the exists. to as find will that goal speaks our the for around present data what towards think just different I and We set. think the talk go different clinicians resonate it

class don’t I the believe will folks look is class the want other this well, to and the and is And look although we the drugs physicians at will the outside infusion. data teriflunomide. best other they or can to rate. impressed that far drugs which we relapse at and relapse and the rate, the in the Many And annualized best. this the the they compare say, have deliver by than look my at in with tolerability will Some patient. Others best speed for be annualized will

not rates the in lines the the just tolerability. infusion. later fourth of about of deliver have infusion continue consistency third to relatively XX% of or infusion. and a of it’s one-hour It’s infusion infusion about one-hour the Ocrevus So, as upwards even high to have to continues XX%, reactions,

third we are by down we the infusion, are something. around I think where or So, X%

a their of but then one-hour I folks towards the a We think we make resumate don’t compare. one standpoint, one-hour comparisons, patient infusion is head. practice infusion. don’t own people obviously, will tolerability Again, standpoint, lot convenience the do convenience will their from the have comparisons in it’s So, resonated toward. a folks And

bag. mixed a it’s think I So,

folks only fats do view assessments will to facts make the they and Our the of the data. present their just job we own how sure is internal and

Prakhar Agrawal

to am you. looking forward Thank December. I

Michael Weiss

you. Thank

Operator

closing I are to would to Thank questions further comments. no Weiss Mike you. hand this like back the There floor time. for over any at

Michael Weiss

for again Great. Thank you. And us everyone, joining this morning. thanks,

date to have Thanks MS approved, We comes option supporting patients chronic for approval are we multiple community. action when patients for believe to times like be of an And the a essential call, this options primary As could great with if PDUFA if us multiple launch target with believe ublituximab joining forms treatment to next XXth, treating with focus morning MS and and is we of a again treatment RMS. goal this remains committed for for December and toward relapsing working it ublituximab meaningful on are day. illnesses being the sclerosis. our early discussed year. And prepared today approved,

Operator

conference. today’s concludes This

You Thank at may lines time. disconnect your you your for participation. this

TG Therapeutics (TGTX) 12 Nov 222022 Q3 Earnings call transcript